May 20, 2018, 3:00 PM
We are writing to notify visitors that the QTdrugs lists were revised on May 20, 2018 and aclarubicin, amsacrine, memantine, maprotiline and cimetidine were added to the lists.
Apr 17, 2018, 3:09 PM
Prescription drug prices are skyrocketing alongside rising healthcare costs. There are many hidden costs associated with the marked rise, and many more questions to be answered surrounding this critical issue. This was the topic of conversation during KVOI’s Bill Buckmaster show during Bills monthly “Your Meds” segment in January of 2017. Dr. Ray Woosley, Founder of CredibleMeds and the Critical Path Institute
Mar 15, 2018, 3:11 PM
CredibleMeds® launches QTFactors.org, a companion database for QTdrugs.org.
Mar 9, 2018, 3:15 PM
Medicines used to treat the rarest of illnesses made up the most expensive prescriptions of 2017. With costs approaching $800,000 per treatment, “orphan drugs” so named because they are used to treat these rare orphan illnesses, are bankrupting patients and their families. What can be done to make these critically important drugs more affordable for those who need it most?
Mar 1, 2018, 3:12 PM
We are writing to inform you that we have added the following three drugs to the QTdrugs lists.
Dec 20, 2017, 3:19 PM
The American opioid epidemic continues to affect millions of Americans every day. What are some of the factors that have led to the current situation, and what can you do to help the fight against this growing problem?
Dec 18, 2017, 3:22 PM
CredibleMeds can now inform users when the FDA label for drugs marketed in the US includes a recommendation for prescreening ECGs,...
Dec 16, 2017, 3:23 PM
We have added the following three drugs to the Possible Risk (PR) of TdP category due to evidence that they are associated with QT prolongation when taken at clinically recommended doses.
Dec 12, 2017, 3:24 PM
We’re pleased to announce that CredibleMeds was recently cited in two major scientific publications of practice guidelines for cardiologists.
Oct 26, 2017, 3:28 PM
QTdrugs lists now can be filtered by market status in US vs non-US